Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Pharma Industry Outlook: What Lies Ahead?

With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

What are the key growth indicators for the global bio/pharmaceutical market in 2023 and over the next five years, and how will the industry perform over this time. That is the operative question for bio/pharma companies and their suppliers, 

Graham Lewis
Vice President,
Global Pharma Strategy
IQVIA

DCAT Week’s flagship program, Pharma Industry Outlook, will answer that question by providing need-to-know market intelligence on the current and projected performance of the bio/pharma industry. Graham Lewis, Vice President of Global Pharma Strategy, IQVIA, a business intelligence firm regarded as the gold standard for bio/pharmaceutical market analysis, will provide the latest market data and trends. 

A key issue is how the industry will perform in the post-pandemic environment with the transition of the global COVID-19 pandemic to a new phase where vaccines and therapeutics are available but are used at different levels and if growth will return to pre-pandemic levels. The program will address these all-important questions:

  • What are the growth prospects globally and in key geographic markets?
  • How is the industry faring in new drug development and what can be expected near term? 
  • Where is the growth in small molecules, biologics, and new modalities such as cell and gene therapies?

Financial outlook for Emerging Pharma
Small bio/pharmaceutical companies play an increasingly important role in product innovation for the industry, but what is the financial outlook for this sector?

Arda Ural,
EY Americas Health Sciences and Wellness Industry Markets Leader, Ernst & Young (EY)

Arda Ural, PhD, EY Americas Health Sciences and Wellness Industry Markets Leader, Ernst & Young (EY), will examine the key trends in industry deal-making and capital flow into Emerging Pharma, a vital customer base for CDMOs/CMOs and partner for bio/pharma companies.  

Pharma Industry Outlook will be held at the InterContinental Barclay Hotel, Grand Ballroom on Monday, March 20, 2023: 2:30 – 4:30 PM; Doors open at 2:00 PM for networking. Plus, Post-Program Attendee Networking Reception: 4:30 to 6:00 PM.  

Register or learn more about this program here. 

Recent Feature Articles

European Parliament Takes Next Step in Reforming EU Pharma Legislation

By
The European Parliament adopted its positions on proposals to revamp the EU‘s pharmaceutical legislation, which includes measures impacting drug development, commercialization, manufacturing & the supply chain. European innovator & generic-drug companies weigh in.

What’s Trending: Generic Drugs by the Numbers & Key Market Developments

By
Generic-drug approvals in the US reached a recent high in 2023 although the number of first-generic approvals were down comparative to recent years. DCAT Value Chain Insights takes a look inside the numbers and the key market moves from the leading generic-drug companies.

The CDMO/CMO and Suppliers Report: Biomanufacturing

By
Driven by increased demand in biologic-based drugs, biomanufacturing (biologic drug substance) continues to be an active area of investment by CDMOs/CMOs, including several multi-billion large-scale biomanufacturing projects. What companies are expanding and where do these expansions stand?

Drug Shortages on the Rise; US Gov’t Proposes New Actions to Address

By
The number of drug shortages in the US has reached a new all-time high, with more than 320 drugs in shortage, according to an analysis by a pharmacist trade group. Earlier this month, the White House proposed new actions to address the problem, including additional requirements for manufacturers.